3D Printed Drugs Market is estimated to grow at a CAGR of 4.3 % during 2022–2027

Posted by kartik joshi on October 4th, 2022

3D Printed Drugs Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Dosage Forms and Technology,” the global 3D printed drugs market is expected to reach US$ 57.03 Mn in 2027 from US$ 28.52 Mn in 2019. The market is estimated to grow at a CAGR of 9.1% during 2020–2027. The report provides trends prevailing in the global 3D printed drugs market, and the driving and restraining factors pertaining to the market growth.

The increasing adoption of personalized medicines and rising awareness regarding 3D printed drugs are the factor driving the growth of the 3D printed market. As per a study published by PMC, personalized medicines accounted for only 5% of the new FDA approved molecular entities in 2005, whereas, in 2016, they accounted for more than 25%. Additionally, 42% of all compounds and 73% of oncology compounds in the pipeline have the potential to function as personalized medicines. Moreover, biopharmaceutical companies have nearly doubled their R&D investments in personalized drugs over the past five years, and they are further likely to increase their investment by 33% in the next five years. Biopharmaceutical researchers also predict a 69% hike in the number of personalized medicines in the next five years.

Sample Report Copy from Here


3D Printed Drugs are medications, which are designed by 3D printing technique to customize for the individuals in a safer and effective way. These drugs have unitary porous structures that readily disperse in the mouth, because of which these high-dose medicines need not to be swallowed intact. The main idea behind 3D printing drugs is to design and develop medicines that are suited to an individual's needs.

Market leaders operating in the market have undertaken various organic growth strategies in the 3D printed drugs market. The 3D printed drugs market majorly consists of the players such APRECIA PHARMACEUTICALS, LLC, FabRx LTD, Cycle Pharmaceuticals, GLAXOSMITHKLINE PLC., ASTRAZENECA, Tvasta, and Merck KGGA amongst others. Several organic approaches, such as product launches, and expansion/relocation in the 3D printed drugs market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.

Below is the list of the growth strategies done by the players operating in the 3D printed drugs market:




Merck entered into strategic collaboration with AMCM with an aim to develop 3D printed tablets. Based on this collaboration, AMCM has agreed to provide its customized additive manufacturing solutions for the manufacturing of 3D printed tablets.


AstraZeneca entered in research collaboration with Quotient Sciences Ltd and Added Scientific Ltd. with an aim to assess the clinical applications of 3D printing for solid dosage forms. Additionally, the pharmaceutical companies also received MRC Confidence in Concepts grant, which will definitely accelerate the research and development activities.


FabRx Ltd. has released the first pharmaceutical 3D printer M3DIMAKER for the manufacture of personalised medicines. The novel system was first introduced at the ILMAC Exhibition in Basel (Switzerland) on the September 2019.


Aprecia Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved SPRITAM levetiracetam for oral use. SPRITAM utilizes Aprecia’s proprietary ZipDose Technology platform.


Contact Us

Phone: +1-646-491-9876

Email Id: sales@theinsightpartners.com

Like it? Share it!

kartik joshi

About the Author

kartik joshi
Joined: September 27th, 2022
Articles Posted: 87

More by this author